KR20230118108A - 항-cd25 항체 - Google Patents

항-cd25 항체 Download PDF

Info

Publication number
KR20230118108A
KR20230118108A KR1020237019908A KR20237019908A KR20230118108A KR 20230118108 A KR20230118108 A KR 20230118108A KR 1020237019908 A KR1020237019908 A KR 1020237019908A KR 20237019908 A KR20237019908 A KR 20237019908A KR 20230118108 A KR20230118108 A KR 20230118108A
Authority
KR
South Korea
Prior art keywords
seq
antibody
antigen
binding fragment
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237019908A
Other languages
English (en)
Korean (ko)
Inventor
다니엘 올리브
아르망 벤수산
제롬 주스티니아니
앤 마리-카르뎅
아르노 푸사
제밀라 후아신
Original Assignee
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)
엥스띠뛰 쟝 빠올리 에 이렌느 깔메뜨
알데란 바이오테크놀로지
상뜨로 나쇼날 드 라 러쉐르쉐 샹띠피크
위니베르시떼 덱스-마르세이유
유니베르시떼 파리 시테
위니베르씨떼 빠리-에스뜨 끄레떼이으 발 드 마른느
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔), 엥스띠뛰 쟝 빠올리 에 이렌느 깔메뜨, 알데란 바이오테크놀로지, 상뜨로 나쇼날 드 라 러쉐르쉐 샹띠피크, 위니베르시떼 덱스-마르세이유, 유니베르시떼 파리 시테, 위니베르씨떼 빠리-에스뜨 끄레떼이으 발 드 마른느 filed Critical 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)
Publication of KR20230118108A publication Critical patent/KR20230118108A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237019908A 2020-11-20 2021-11-19 항-cd25 항체 Pending KR20230118108A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20306424 2020-11-20
EP20306424.1 2020-11-20
PCT/EP2021/082383 WO2022106665A1 (en) 2020-11-20 2021-11-19 Anti-cd25 antibodies

Publications (1)

Publication Number Publication Date
KR20230118108A true KR20230118108A (ko) 2023-08-10

Family

ID=73698744

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237019908A Pending KR20230118108A (ko) 2020-11-20 2021-11-19 항-cd25 항체

Country Status (9)

Country Link
US (1) US20240002522A1 (https=)
EP (1) EP4247497A1 (https=)
JP (1) JP2023550446A (https=)
KR (1) KR20230118108A (https=)
CN (1) CN116917318A (https=)
AR (1) AR124123A1 (https=)
AU (1) AU2021380966A1 (https=)
CA (1) CA3199006A1 (https=)
WO (1) WO2022106665A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222886A1 (en) 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US61816A (en) 1867-02-05 bunbab and a
US96973A (en) 1869-11-16 saxton
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
PL2602323T3 (pl) 2007-06-01 2018-06-29 Open Monoclonal Technology, Inc. Kompozycje i sposoby hamowania endogennych genów immunoglobin i wytwarzania transgenicznych ludzkich przeciwciał typu idiotypowego
US11879014B2 (en) * 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
EP3649153B8 (en) * 2017-07-06 2025-07-16 Tusk Therapeutics Ltd Fc optimised anti-cd25 antibodies for tumor specific cell depletion
US10752691B2 (en) * 2018-03-13 2020-08-25 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
EP3972997A1 (en) * 2019-05-20 2022-03-30 Institut National de la Santé et de la Recherche Médicale (INSERM) Novel anti-cd25 antibodies

Also Published As

Publication number Publication date
CA3199006A1 (en) 2022-05-27
JP2023550446A (ja) 2023-12-01
CN116917318A (zh) 2023-10-20
EP4247497A1 (en) 2023-09-27
US20240002522A1 (en) 2024-01-04
AU2021380966A1 (en) 2023-06-22
AR124123A1 (es) 2023-02-15
WO2022106665A1 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
US12415854B2 (en) Antibodies to TIGIT
JP7834028B2 (ja) Ｉｌｔ結合剤及びその使用方法
US20220251232A1 (en) Novel anti-cd25 antibodies
RU2725811C1 (ru) Антитела против 4-1bb человека и их применение
EP3589654A1 (en) Antibodies having specificity to nectin-4 and uses thereof
US20240002521A1 (en) Anti-cd25 antibodies
US12577324B2 (en) Antibodies having specificity to HER4 and uses thereof
KR20230118108A (ko) 항-cd25 항체
KR20190117467A (ko) IFN-γ-유도성 조절 T 세포 전환가능 항암 (IRTCA) 항체 및 그의 용도
WO2024163530A2 (en) Novel anti-ccr4 antibodies and derivative products
US20240382592A1 (en) Methods for the treatment of anaplastic large cell lymphoma
CA3176246C (en) Antibodies to tigit
WO2023143478A1 (en) Novel anti-cd4 and anti-pd-l1 bispecific antibodies
WO2023222886A1 (en) Antibody-cytokine fusion proteins
EA049282B1 (ru) Антитела к tigit
HK40088961A (zh) 抗tigit抗体
CN115698070A (zh) Cd5l结合抗体及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230613

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241118

Comment text: Request for Examination of Application